CAS: 320-51-4; 4-Chloro-3-(Trifluoromethyl)Aniline

上下游产品

CAS号99586-65-9 4-氯吡啶-2-甲酰胺 | CAS号123-30-8 对氨基苯酚 | CAS号777-37-7 2-氯-5-硝基三氟甲苯 | CAS号98-16-8 间三氟甲苯胺 | CAS号445-01-2 5-溴-2-氯三氟甲苯 | CAS号88-16-4 2-氯三氟甲苯 | CAS号369-77-7 N-(4-氯苯基)-N'-[4... | CAS号1198619-79-2 1-(4-bromopheny... | CAS号100-46-9 苄胺 | CAS号370-50-3 1,3-二[4-氯-3-(三氟... | CAS号327-78-6 4-氯-3-三氟甲基异氰酸苯酯 | CAS号34328-46-6 4-氯-3-三氟甲基苯甲醛 | CAS号400-73-7 4-氯-3-三氟甲基苯甲醚 | CAS号89634-75-3 2-氯-5-氟三氟甲苯 | CAS号6294-93-5 4-氯-3-三氟甲基苯酚 | CAS号284461-73-0 索拉非尼 | CAS号284462-37-9 4-(4-氨基苯氧基)-N-甲... | CAS号1130115-44-4 Bay 43-9006-d3 | CAS号343247-69-8 N-[4-氯-3-(三氟甲基)苯基]脲

2-氯-5-硝基三氟甲苯置于氢气体系中,用 乙醇 用作溶剂,99.84 °C,4.0 Mpa 条件下,反应 7.0H,反应生成2-氯-5-氨基三氟甲苯
参考文献:钯在co-Sio2核壳纳米催化剂中对氯硝基芳烃选择性液相加氢的促进作用
标题:钯在co-Sio2核壳纳米催化剂中对氯硝基芳烃选择性液相加氢的促进作用
摘要:这项研究描述了钯催化的co @ Sio 2催化剂的合成,该催化剂是通过将pd离子前体静电固定在涂有中孔sio 2壳的co 3 O 4纳米颗粒核上而开发的.氧化的pd-Co 3 O 4 @sio 2(xpdco-Ox)和部分还原的pd-Co @ Sio 2(xpdco-Red)纳米催化剂被用于采用异质加氢工艺从氯硝基芳烃直接合成氯芳基胺.Co 3 O 4中钯含量(xpdco; X = 0.0,0.5,1.0和3.0 Pd Wt%)的影响系统地研究了结构的核心对4-氯硝基苯(cnb)加氢成4-氯苯胺(can)催化性能的影响.已经发现,与原始co-Sio 2核-壳结构相比,钯离子前体的掺入既促进了co 3 O 4核纳米颗粒的絮凝,也促进了pd促进的催化剂中介孔壳厚度的增加.Tpr,Xrd,Xps和磁测量结果表明,在等温h 2期间,钯的加入促进了co 3 O 4核的还原.在873 K下进行处理,得
Doi:10.1016/j.Jcat.2020.03.006

专利信息

专利号:US-2009253913-A1
优先权日:2008-03-06
标题:Process for the preparation of sorafenib and salts thereof
发明人：ROSSETTO PIERLUIGI; MACDONALD PETER LINDSAY; CANAVESI AUGUSTO
权利人:ROSSETTO PIERLUIGI; MACDONALD PETER LINDSAY; CANAVESI AUGUSTO
摘要:Methods for the synthesis of the N-carbamoyl imidazole (I) and its 1:1 adduct with imidazole are provided. Methods for the preparation of these crystalline intermediates in a high state of purity are also provided. These intermediates react cleanly under mild conditions to produce sorafenib in high yield and purity, without generating difficult-to-remove impurities.

专利号:US-8735391-B2
优先权日:2008-09-26
标 题 :Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
发明人：AUBE JEFFREY; ROTH BRYAN L; GHOSH PARTHA; FRANKOWSKI KEVIN J
权利人:AUBE JEFFREY; ROTH BRYAN L; GHOSH PARTHA; FRANKOWSKI KEVIN J; UNIV KANSAS
摘要:A functionalized polycyclic compound can have a structure of Formula 1 or salt, prodrug, analog, or derivative thereof, which compound can be prepared by providing a diene; reacting the diene with a dienophile under sufficient conditions for a combined Diels-Alder/acylation reaction so as to provide a polycyclic compound having a carboxylic acid; and coupling the carboxylic acid with an amine-containing compound or a hydroxyl-containing compound so as to form an amide or an ester and producing a compound having a structure of Formula 1. The compound can be used for modulating an opioid receptor, which can be conducted by administering to an opioid receptor a functionalized polycyclic compound as described herein in an effective amount to modulate the functionality of the opioid receptor. Such opioid modulation can provide a biological benefit to a subject.

专利号:WO-2024168196-A1
优先权日:2023-02-08
标 题:Systems and methods for enzymatic synthesis of polynucleotides containing non-standard nucleotide basepairs
发明人：MARCHAND JORGE; KAWABE HINAKO
权利人:UNIV WASHINGTON
摘要:Systems and methods for generating defined base pairs in a sequence-defined library format that include at least one non-standard nucleotide in a base pair. Non-standard base pairs can be created using a nucleic acid polymerase ( e.g. , DNA polymerase, RNA polymerase, terminal deoxynucleotide polymerase) for blunt-end tailing addition of the non-standard base, which then can be ligated to another nucleotide end. The nucleotide sequences containing non-standard base pairs can be used to generate libraries for basecalling models of the non-standard base with next-generation sequencing (NGS) platforms and sequencing non-standard nucleotide sequences, including xenonucleotide (XNAs).

专利号:US-6849650-B2
优先权日:1998-02-27
标 题:Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
发明人：THORSETT EUGENE D; PORTER WARREN J; NISSEN JEFFREY S; LATIMER LEE H; AUDIA JAMES E; DROSTE JAMES
权利人:ATHENA NEUROSCIENCES INC; LILLY CO ELI
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

专利号:US-6399628-B1
优先权日:1996-11-22
标 题 :N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
发明人：AUDIA JAMES E; FOLMER BEVERLY K; JOHN VARGHESE; LATIMER LEE H; NISSEN JEFFREY S; REEL JON K; THORSETT EUGENE D; WHITESITT CELIA A
权利人:ATHENA NEUROSCIENCES INC; LILLY CO ELI
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

专利号:EP-0951466-B1
优先权日:1996-12-23
标题:Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
发明人：WU JING; TUNG JAY S; THORSETT EUGENE D; PLEISS MICHAEL A; NISSEN JEFFREY S; NEITZ JEFFREY; LATIMER LEE H; JOHN VARGHESE; FREEDMAN STEPHEN; BRITTON THOMAS C; AUDIA JAMES E; REEL JON K; MABRY THOMAS E; DRESSMAN BRUCE A; CWI CYNTHIA L; DROSTE JAMES J; HENRY STEVEN S; MCDANIEL STACEY L; SCOTT WILLIAM L; STUCKY RUSSELL D
权利人:ELAN PHARM INC; LILLY CO ELI
摘要:Disclosed are compounds for Formula (I) wherein the substituents are as defined in the claims which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.